RIMSO-50 Shortage: What Providers and Prescribers Need to Know in 2026

RIMSO-50 (dimethyl sulfoxide, 50% w/w intravesical solution) is the only FDA-approved bladder instillation therapy for interstitial cystitis/bladder pain syndrome (IC/BPS). As such, supply disruptions — even localized ones — have an outsized impact on a patient population that is already living with a chronic, painful condition.

This guide is written specifically for urologists, urogynecologists, and other providers who prescribe and administer RIMSO-50. It covers supply chain context, clinical implications of disruptions, evidence-based alternatives, and patient communication strategies for 2026.

Current Supply Situation in 2026

As of 2026, RIMSO-50 does not carry an active FDA Drug Shortage designation. However, providers continue to report inconsistent supply through specialty and wholesale distributors. This reflects a structural challenge inherent to RIMSO-50's supply chain rather than a discrete manufacturing failure.

Both brand-name RIMSO-50 (Mylan) and generic dimethyl sulfoxide 50% intravesical solution (Sandoz) are FDA-approved and bioequivalent. Practices experiencing RIMSO-50 brand availability issues should verify whether the Sandoz generic is available through their current distributors, as it may be stocked separately.

Why RIMSO-50 Supply Is Structurally Fragile

Several factors make RIMSO-50 susceptible to localized availability issues:

Limited distribution network: RIMSO-50 does not flow through standard retail pharmacy channels. It is sourced primarily through specialty and hospital pharmaceutical wholesalers, limiting the number of redundant supply pathways.

Small commercial market: As a niche drug for a specific patient population, RIMSO-50 does not command the same supply chain prioritization as high-volume medications.

Infrequent practice ordering: Since instillations are given biweekly, some practices order on reactive rather than proactive cycles, creating intermittent stockouts.

Historical compounding safety concerns: At the AUA 2013 Annual Meeting, Dr. Robert Moldwin reported that at least one compounding pharmacy was shipping industrial-grade DMSO to urology clinics. Practices sourcing from non-standard channels must verify pharmaceutical-grade certification.

Clinical Impact of Treatment Delays in IC/BPS

IC/BPS is a chronic condition with significant impact on quality of life. Disruptions to the standard biweekly instillation schedule can lead to:

Recurrence of bladder pain and pelvic pressure

Worsening urinary urgency and frequency

Increased patient anxiety, depression, and reduced quality of life

Potential loss of treatment gains achieved during an initial series

Research indicates that DMSO is particularly effective for Hunner type IC (HIC) — patients with Hunner lesions tend to show the strongest response. Any disruption in therapy for this subgroup is especially problematic, as symptom recurrence may be more severe.

Evidence-Based Alternatives When RIMSO-50 Is Unavailable

Providers should be prepared with evidence-informed alternatives for patients whose DMSO therapy must be interrupted:

Intravesical heparin: Anti-inflammatory and GAG-layer protective; data supports it as both a bridge therapy and maintenance option after DMSO. One study showed monthly heparin maintenance reduces DMSO relapse rate from 52% to 20%.

Alkalinized lidocaine/heparin cocktail: Lidocaine 1–2% with sodium bicarbonate, with or without heparin, is a well-supported office or home instillation option. The AUA IC guidelines list this as a recommended treatment.

BTH cocktail (bupivacaine, triamcinolone, heparin): A 2020 RCT demonstrated BTH provided significant symptom improvement in newly diagnosed IC/BPS patients comparable to DMSO in many domains, with DMSO showing stronger bladder pain relief.

Elmiron (pentosan polysulfate sodium): The only FDA-approved oral IC therapy. Slow onset (2–6 months). Useful as a background treatment but not a substitute for acute instillation benefit. Monitor for pigmentary maculopathy with annual ophthalmologic exams.

Tricyclic antidepressants (amitriptyline, imipramine): Reduce bladder pain and urgency; AUA guideline-recommended. Start at 10–25 mg at bedtime and titrate.

Practical Recommendations for Practices Experiencing Supply Issues

Establish relationships with 2–3 specialty distributors to create redundant supply pathways.

Proactively confirm RIMSO-50 stock 2+ weeks ahead of scheduled instillations, especially for high-frequency patients.

Keep a supply of heparin and lidocaine on hand as a bridge when RIMSO-50 is delayed.

Verify that all DMSO products used in your clinic are pharmaceutical-grade (RIMSO-50 brand or Sandoz generic) — never industrial or veterinary grade.

Refer patients to medfinder for providers — a service that helps patients find pharmacies in their area that can fill their prescriptions.

Communicating With Patients About Supply Disruptions

Patients with IC often experience significant medical anxiety, particularly when a treatment that is working becomes unavailable. Clear, proactive communication is essential. Notify patients as soon as a supply issue is identified — do not wait until the scheduled appointment. Provide a specific plan, not just a vague reassurance, and outline the bridge therapy options available during the gap.

See also: How to Help Your Patients Find RIMSO-50 in Stock: A Provider's Guide.